Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.

scientific article published on 12 April 2010

Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1001969954
P356DOI10.1038/BMT.2010.64
P698PubMed publication ID20383212
P5875ResearchGate publication ID43100174

P2093author name stringK Sakashita
M Tanaka
S Saito
K Koike
M Shiohara
R Yanagisawa
T Shigemura
Y Nakazawa
Y Katsuyama
P2860cites workTacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantationQ31418325
Practical considerations in the use of tacrolimus for allogeneic marrow transplantationQ33782457
Engraftment syndrome following hematopoietic stem cell transplantationQ34298239
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patientsQ36499377
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantationQ40385566
Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasomeQ40425731
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.Q40658076
Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantationQ43710389
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignanciesQ44137979
Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) geneQ44157253
Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene PolymorphismsQ44402549
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytesQ44729971
Tacrolimus clearance is age-dependent within the pediatric populationQ45871846
Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipientsQ46434574
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patientsQ46647761
A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemiaQ47575405
Dexamethasone modulation of multidrug transporters in normal tissues.Q54106487
Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes.Q54235409
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donorsQ70051817
Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantationQ73338170
Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipientsQ73533045
Tacrolimus pharmacokinetics in BMT patientsQ74256230
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)90-97
P577publication date2010-04-12
P1433published inBone Marrow TransplantationQ4941523
P1476titleEngraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.
P478volume46

Reverse relations

cites work (P2860)
Q53706894A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients.
Q38748975Clinical determinants of calcineurin inhibitor disposition: a mechanistic review
Q26798470Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children
Q44133007Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
Q53175337Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.

Search more.